MedTrace Logo

Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

NCT03692143 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2018-10-02

No results posted yet for this study

Summary

This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.

Conditions

  • Osteoporosis, Postmenopausal
  • Vertebral Fracture
  • Quality of Life

Interventions

DRUG

Teriparatide

subcutaneous injection of teriparatide(20 mg) once daily

PROCEDURE

PVP

With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously

DRUG

Alendronate

Alendronate Sodium, oral, 70mg, once a week

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Dehong Yang, MD,PhD · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
49 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2025-03-01
Completion
2030-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692143 on ClinicalTrials.gov